StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Restasis [legacy through FY24] by Quarter

Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

AbbVie Restasis [legacy through FY24]: 19.7% in Q4 2024, down 31.7 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2024
19.7%
Period ended Dec 31, 2024
Change on a year earlier
-31.7 pts
51.4% in Q4 2023
History
14 quarters
Since Q3 2021
Sources
14
Documents cited below

Where the Q4 2024 figure comes from

“|| Restasis | 102 | 12 | 114 | (13.7) | 14.9 | (11.3) | 19.7 | (10.9)”

Source: Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRestasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q4 2024Dec 31, 202419.7%-31.7 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 20248.1%-34.0 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-14.5%-19.7 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 20244.1%-21.0 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202351.4%+96.4 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 202342.1%+79.8 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 20235.2%-19.0 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 202325.1%+23.2 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-45.0%-77.8 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-37.7%-31.2 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗
Q2 2022Jun 30, 202224.2%–Form 8-K (abbv-20220630xexhibit991.htm, filed 2022-07-29) ↗
Q1 2022Mar 31, 20221.9%–Form 8-K (abbv-20220331xexhibit991.htm, filed 2022-04-29) ↗
Q4 2021Dec 31, 202132.8%–Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
Q3 2021Sep 30, 2021-6.5%–Form 8-K (abbv-20210930xexhibit991.htm, filed 2021-10-29) ↗

Cite this data

StockData. (2026). AbbVie Restasis [legacy through FY24] (%), quarterly Q3 2021–Q4 2024 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/restasis-intl-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.